Lifeward Ltd. (NASDAQ: LFWD), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second-quarter 2026 financial results on Friday, August 14. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET.
Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives.
This morning’s news release goes on to say the Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit.
These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population.
The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms.
This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market.
LFWD shares closed Thursday at $7.40.
